Proposal to fund immunotherapy for stage 4 lung cancer is a GIANT step forward
“This funding proposal meets the greatest treatment need right now with the gold standard for lung cancer and it will be life changing for stage 4 non-small cell lung cancer patients (approx. 1200 per year).”
“We are ever grateful to the huge number of brave patients and their family’s who have added impact to our collective advocacy by sharing their story. We also remember with admiration and utmost respect so many patients no longer with us. We will never forget them.”
We acknowledge the team at Pharmac, the key people at Merck Sharp & Dohme New Zealand and Roche New Zealand, the specialists, health leaders and advocates who have worked together to deliver this funding proposal.
– Pembrolizumab (brand name Keytruda by Merck Sharp & Dohme New Zealand) would be funded for the first line treatment of advanced non-small cell lung cancer.
– Atezolizumab (brand name Tecentriq by Roche New Zealand)would be funded for the second line treatment of advanced non-small cell lung cancer.
Click to view our statement –
